References

Understanding COVID-19-associated coagulopathy

10.1038/s41577-022-00762-9 · 2022 · External reference

Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19

10.1182/blood.2020007252 · 2020 · External reference

Platelet gene expression and function in patients with COVID-19

10.1182/blood.2020007214 · 2020 · External reference

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

10.1172/jci141374 · 2020 · External reference

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

10.1182/blood.2020007008 · 2020 · External reference

Neutrophil extracellular traps in COVID-19

2020 · External reference

Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19

10.1126/scitranslmed.abd3876 · 2020 · External reference

Increased histone-DNA complexes and endothelial-dependent thrombin generation in severe COVID-19

10.1016/j.vph.2021.106950 · 2022 · External reference

The role of extracellular histones in COVID-19

10.1111/joim.13585 · 2023 · External reference

COVID-19 and sepsis are associated with different abnormalities in plasma procoagulant and fibrinolytic activity

10.1161/atvbaha.120.315338 · 2021 · External reference

Thrombin generation in patients with COVID-19 with and without thromboprophylaxis

10.1515/cclm-2021-0108 · 2021 · External reference

Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis

10.1111/jth.15660 · 2022 · External reference

Extracellular histones: a unifying mechanism driving platelet-dependent extracellular vesicle release and thrombus formation in COVID-19

10.1016/j.jtha.2024.05.019 · 2024 · External reference

Regulation of coagulation by tissue factor pathway inhibitor: implications for hemophilia therapy

10.1111/jth.15697 · 2022 · External reference

Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays

10.1111/ijlh.13329 · 2021 · External reference

Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy

10.1007/s11239-021-02583-4 · 2022 · External reference

Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection

10.1016/j.eclinm.2021.101069 · 2021 · External reference

Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial

10.1111/jth.15450 · 2021 · External reference

Thrombotic potential during pediatric acute lymphoblastic leukemia induction: role of cell-free DNA

10.1002/rth2.12557 · 2021 · External reference

DNase 1 protects from increased thrombin generation and venous thrombosis during aging: cross-sectional study in mice and humans

10.1161/jaha.121.021188 · 2022 · External reference

Major reservoir for heparin-releasable TFPIα (tissue factor pathway inhibitor alpha) is extracellular matrix

10.1161/atvbaha.120.315728 · 2021 · External reference

Extracellular histones: a unifying mechanism driving platelet-dependent extracellular vesicle release and thrombus formation in COVID-19

10.1016/j.jtha.2024.05.019 · 2024 · External reference

Clinical predictors of COVID-19 severity and mortality: a perspective

10.3389/fcimb.2021.674277 · 2021 · External reference

Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and protein S

10.1002/rth2.12058 · 2018 · External reference

Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients

10.1038/s41598-021-85906-y · 2021 · External reference

Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality-brief report

10.1161/atvbaha.120.315547 · 2021 · External reference

Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19

10.1182/bloodadvances.2020003308 · 2021 · External reference

Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation

10.1073/pnas.1310444110 · 2013 · External reference

Evaluation of protein C and S levels in patients with COVID-19 infection and their relation to disease severity

10.1186/s43162-023-00195-3 · 2023 · External reference

Dysregulation of protein S in COVID-19

10.1016/j.beha.2022.101376 · 2022 · External reference

Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins

10.1055/s-0037-1615755 · 2001 · External reference